
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is a medical technology company with a focus on predictive medical diagnostics. Its DeepView System, which has been in development and clinical investigation for numerous years, uses AI algorithms to assess the healing potential of burn wounds. The recent FDA clearance for DeepView is a significant milestone and is expected to lead to early commercial adoption of the system supported by BARDA funding. With a large market potential and a license model that is expected to drive recurring revenue, Spectral AI has the potential for stable growth. The achievement of this milestone has resulted in a raised price target of $4 from $3, and the company is expected to see revenue growth of over 110% CAGR in FY26 through FY30 upon commercial launch of DeepView. However, some risks to consider include potential delays in clinical and regulatory developments, as well as competition in the market.
Bears say
Spectral AI is a promising AI company focused on the predictive medical diagnostics market, with its DeepView system offering innovative technology for assessing and treating burns and wounds. However, the company faces significant challenges in gaining regulatory clearance and commercial adoption in the highly fragmented and under-penetrated wound care market. Additionally, while the BARDA contract may provide some initial revenue, sustained profitability may be difficult to achieve without further indications or sources of non-dilutive financing for international sales.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares